Company news
Vistagen Therapeutics, Inc. news in 2020
Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders
December 29, 2020
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
December 21, 2020
VistaGen Therapeutics Announces Pricing of Underwritten Public Offering
December 17, 2020
VistaGen Therapeutics Announces Proposed Underwritten Public Offering
December 16, 2020
VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression
December 9, 2020
VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress
November 11, 2020
VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid
September 2, 2020
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
August 12, 2020
VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering
August 9, 2020
VistaGen Therapeutics Announces Closing of $12.5 Million Underwritten Public Offering
August 4, 2020
VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration
August 3, 2020
VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock
August 1, 2020
VistaGen Therapeutics Announces Proposed Public Offering of Common Stock
July 30, 2020
VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder
July 22, 2020
VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update
June 28, 2020
VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia
June 24, 2020
VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions
May 26, 2020
VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
May 17, 2020
VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19
April 27, 2020
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
March 24, 2020
VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder
February 19, 2020
VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
February 12, 2020
VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects
February 10, 2020
VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients
January 29, 2020
Decks in 2020
- Investor Presentation (October 2020)
Investor deck · 39 slides · Oct 13, 2020
- Investor Presentation (August 2020)
Investor deck · 37 slides · Aug 14, 2020
- Investor Presentation (July 2020)
Investor deck · 35 slides · Jul 24, 2020
- Investor Presentation (June 2020)
Investor deck · 36 slides · Jun 1, 2020
- Investor Presentation (April 2020)
Investor deck · 46 slides · Apr 3, 2020